AgomAb Therapeutics NV

AI-generated fair value estimate for this company.

Method: Sum-of-the-parts risk-adjusted NPV (rNPV): $286.9M net cash (EUR252.0M as of 6/30/26 converted at 1.1385 EUR/USD); lead asset (ontunisertib, Phase 2b fibrostenosing Crohn's disease, FDA-aligned pivotal trial design) valued via rNPV using $2.0B estimated peak sales, 30% peak operating margin, 25% probability of technical/regulatory success, 12% discount rate, launch approximately 2032, 10-year sales annuity (approximately $429M PV); second asset (AGMB-447, Phase 1b idiopathic pulmonary fibrosis) valued similarly with $800M peak sales and 10% probability of success (approximately $55M PV); 49.25M shares outstanding.

Reasoning: AgomAb is a pre-revenue clinical-stage biopharmaceutical company, so a conventional FCF DCF is not applicable; the standard, most rigorous approach for clinical-stage biotech is a sum-of-the-parts model combining net cash with a probability-of-success-adjusted NPV of each pipeline program, sized using realistic peak-sales and margin assumptions for the target indications and discounted for the multi-year development timeline.